-
-
Small Molecule Drug Platform
-
Chiral Catalysis Technology
-
Continuous Flow Technology
-
Fluorine Chemistry
-
Enzyme Catalysis
-
Photocatalysis
-
Solid-State Research
显示更多 -
-
Drug Product (DP) Platforms
-
Sustained and Controlled Release
-
Solubility Enhancement
-
Topical Formulation
-
Liquid Formulation
-
Softgels
-
Flow-through cell
显示更多 -
-
Peptide Platform
显示更多 -
Research Team
显示更多
-
![](/npublic/img/s.png)
Intellectual Property (IP) Protection
We formulated various policies, such as theIntellectual Property Protection Policy and Intellectual Property Handbook, in accordance with the Civil Code of the People's Republic of China, the Trademark Law of the People's Republic of China, the Patent Law of the People's Republic of China, the Copyright Law of the People's Republic of China, and other applicable laws and regulations. We also passed the GB/T 29490-2013 Intellectual Property Management System Certification applicable to IPs in the R&D, production, and sales of APIs and intermediates for central nervous system, anti-infective, anti-tumor, hypoglycemic, cardiovascular, and non-steroidal anti-inflammatory agents.
To protect our IP rights, we have set up the Patent Information Department for patent application, maintenance, protection, and information retrieval, and developed a solid IP management system and protection procedures.
To avoid infringing upon others' IP rights, we retrieve relevant patent information before starting a project, perform IP due diligence during the project review, including a review of the patent application and legal status of the product or key technology that is involved in a project before project initiation, and issue a patent retrieval report for risk warning.
Our Patents
Other Quality and Compliance
Business Collaboration
Innovative Drug CDMO Services
![Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Zhejiang Jiuzhou Pharmaceutical Co., Ltd.](https://omo-oss-image.thefastimg.com/portal-saas/new2023050917060170378/cms/image/af9820f2-7496-4bb9-a939-cbf57718f448.jpg)